Form 4: NewAmsterdam Pharma Director Acquires Shares and Options

Director Adele M. Gulfo acquired shares and options in NewAmsterdam Pharma Co N.V. on April 15, 2025.

Summary

• On April 15, 2025, Adele M. Gulfo, a director of NewAmsterdam Pharma Co N.V., acquired 10,860 ordinary shares.
• These shares were obtained through restricted stock units (RSUs), each representing a contingent right to receive one ordinary share.
• The RSUs vest in three equal installments on the first, second, and third anniversaries of the vesting start date, contingent upon continued service.
• Gulfo also acquired an option to buy 50,700 ordinary shares at an exercise price of $16.06.
• 33% of the shares underlying the option will vest on April 15, 2026, with the remaining shares vesting in equal monthly installments over the following two years, subject to continued service.

Sentiment

Score: 7

Explanation: Director's acquisition of shares and options is generally a positive sign, indicating confidence in the company's future prospects. The vesting schedules also suggest a long-term commitment.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.

Future Outlook

The vesting schedules for both the RSUs and options are contingent upon the reporting person's continued service, suggesting a long-term commitment to the company.

Industry Context

Director share acquisitions are common in the pharmaceutical industry and are often viewed positively by investors as they align management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive signal.

Key Dates

Keywords

NewAmsterdam Pharma, Director, Share Acquisition, Options, RSUs, Form 4, Beneficial Ownership